Introduction & Objective: To assess, post hoc, the impact of ethnicity and race on the efficacy and hypoglycemia rates with once-weekly (OW) insulin icodec (icodec) vs once-daily (OD) basal insulin in adults with T2D.

Methods: Efficacy and safety outcomes were assessed within each trial across ethnic (Hispanic/Latino vs non-Hispanic/Latino) and race (Asian, Black/African American, White, Other) subgroups in insulin-naïve (ONWARDS [ON] 1, 3, 5) and insulin-treated (ON 2, 4) adults with T2D.

Results: Across all trials, no statistically significant interaction between treatment and subgroup for improvements in A1C were seen with icodec vs OD insulin (baseline to planned end of treatment) (Figure). Hypoglycemia rates were low in both treatment groups across ethnicities and races, precluding statistical analysis. A greater proportion of individuals in most ethnic and racial subgroups across trials achieved A1C < 7% without clinically significant or severe hypoglycemia with icodec vs OD insulin (no statistically significant treatment by subgroup interaction).

Conclusion: A1C and hypoglycemia endpoints were consistent for OW icodec vs OD insulin, irrespective of ethnicity or race.

graphic
View largeDownload slide
Disclosure

I. Lingvay: Consultant; Altimmune, Astra Zeneca, Bayer, Biomea, Boehringer-Ingelheim, Carmot, Cytoki Pharma, Eli Lilly, Intercept, Janssen/J&J, Mannkind, Mediflix, Merck, Metsera, Novo Nordisk, Pharmaventures, Pfizer, Sanofi. Research Support; NovoNordisk, Sanofi, Mylan, Boehringer-Ingelheim. Consultant; TERNS Pharma, The Comm Group, Valeritas, WebMD, and Zealand Pharma. K.O. Bangsgaard: Employee; Novo Nordisk A/S. C. Desouza: Advisory Panel; Novo Nordisk, Bayer Inc., Madrigal Pharmaceuticals, Inc. Other Relationship; ADA/ACC Diabetes by Heart Program. Advisory Panel; Asahi Kasei. M. Fragão Marques: None. A. Navarria: Employee; Novo Nordisk A/S, Rhythm Pharmaceuticals, Inc. A.G. Vianna: Board Member; Abbott, Lilly Diabetes, Novo Nordisk, Medtronic. Speaker's Bureau; AstraZeneca, Novo Nordisk. Research Support; Novo Nordisk, Lilly Diabetes. Speaker's Bureau; Lilly Diabetes. Research Support; Servier Laboratories.

Funding

Novo Nordisk A/S

© 2024 by the American Diabetes Association
2024
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.